RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients’ Microbiomes in a Phase 1 Study for Recurrent Clostridioides difficile Infections

BACKGROUND: Recurrent Clostridioides difficile infections (rCDI) are a global public health threat. To reduce rCDI, microbiota-restoring therapies are needed, particularly standardized, easy-to-administer formulations. METHODS: This phase I open-label trial assessed the safety, efficacy in preventin...

Descripción completa

Detalles Bibliográficos
Autores principales: Khanna, Sahil, Pardi, Darrell S, Jones, Courtney, Shannon, William D, Gonzalez, Carlos, Blount, Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Online Only Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492147/
https://www.ncbi.nlm.nih.gov/pubmed/32966574
http://dx.doi.org/10.1093/cid/ciaa1430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492147/
https://www.ncbi.nlm.nih.gov/pubmed/32966574
http://dx.doi.org/10.1093/cid/ciaa1430

Ejemplares similares